Neurocode USA Inc, a leading clinical laboratory specializing in blood biomarkers for Alzheimer’s disease (AD) diagnosis, is pleased to announce the publication of a groundbreaking new study comparing the performance of two prominent pTau217 assays: the ALZpath assay and the Fujirebio assay.